Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 13, 2026, 5:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Botulinum Toxin Injection Clear all
Completed Not applicable Interventional Results available

Onabotulinumtoxin A Versus Kenalog for Chronic Pelvic Pain

NCT02369068
View directory record Official record
Conditions
Pelvic Pain
Interventions
Onabotulinumtoxin A, Kenalog
Drug
Lead sponsor
Jamie Bartley, DO
Other
Eligibility
18 Years and older · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Sep 13, 2026, 5:59 AM EDT
Withdrawn Phase 2 Interventional

Efficacy Study of Botulinum Toxin (BOTOX) Injections to Treat Vocal Fold Granulomas

NCT01678053
View directory record Official record
Conditions
Contact Ulcer of Vocal Folds, Granuloma of Vocal Cords, Granuloma, Laryngeal, Granuloma
Interventions
onabotulinumtoxinA, omeprazole (proton pump inhibitor)
Drug
Lead sponsor
Phillip Song, MD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Sep 13, 2026, 5:59 AM EDT
Completed Phase 2 Interventional

Study of BOTOX Injections to Assess Change in Disease Activity and Adverse Events in Adult Female Participants With Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)

NCT05141006
View directory record Official record
Conditions
Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)
Interventions
BOTOX, Placebo for BOTOX
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
40
States / cities
Homewood, Alabama • Mobile, Alabama • Buena Park, California + 32 more
Source: ClinicalTrials.gov public record
Updated May 5, 2025 · Synced Sep 13, 2026, 5:59 AM EDT
Completed No phase listed Observational

Muscle Elastography in Spastic Cerebral Palsy

NCT03112434
View directory record Official record
Conditions
Unilateral Spastic Cerebral Palsy
Interventions
Botulinum toxin type A
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
5 Years to 18 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 20, 2022 · Synced Sep 13, 2026, 5:59 AM EDT
Terminated Phase 3 Interventional Results available

Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 1

NCT02660138
View directory record Official record
Conditions
Urinary Incontinence, Overactive Bladder
Interventions
Botulinum toxin type A, Placebo
Biological · Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years to 80 Years
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
32
States / cities
Birmingham, Alabama • Tucson, Arizona • Long Beach, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Sep 13, 2026, 5:59 AM EDT
Not yet recruiting Early Phase 1 Interventional

A Novel Medical System for Quantitative Diagnosis and Personalized Precision Botulinum Neurotoxin Injection in Chronic Pelvic Pain Management

NCT05062902
View directory record Official record
Conditions
Interstitial Cystitis, Chronic Pain, Pelvic Floor; Relaxation, Pelvic Floor Disorders
Interventions
High Density Surface Electromyographic, precision botulinum neurotoxin injection guidance medical device, Botulinum Neurotoxin
Device · Drug
Lead sponsor
HillMed Inc.
Industry
Eligibility
18 Years to 60 Years · Female only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 18, 2025 · Synced Sep 13, 2026, 5:59 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of Botulinum Toxin for the Treatment of Glabellar Frown Lines

NCT02236312
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
Botulinum Toxin Type A, Placebo
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
359 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
8
States / cities
Birmingham, Alabama • Mobile, Alabama • San Diego, California + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2022 · Synced Sep 13, 2026, 5:59 AM EDT
Completed Phase 2 Interventional Results available

Botulinum Toxin Type A (AGN-151607) for the Prevention of Post-operative Atrial Fibrillation in Adult Participants Undergoing Open-chest Cardiac Surgery (NOVA)

NCT03779841
View directory record Official record
Conditions
Post-Operative Atrial Fibrillation
Interventions
AGN-151607, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
55 Years to 90 Years
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
19
States / cities
Stanford, California • New Haven, Connecticut • Washington D.C., District of Columbia + 16 more
Source: ClinicalTrials.gov public record
Updated May 13, 2024 · Synced Sep 13, 2026, 5:59 AM EDT
Terminated Phase 4 Interventional Results available

BOTOX Effects on Seizure Severity and Susceptibility

NCT05605756
View directory record Official record
Conditions
Drug-resistant Focal Seizure
Interventions
OnabotulinumtoxinA 145 UNT [Botox]
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Sep 13, 2026, 5:59 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate Sequential Administration of AGN-151586 and OnabotulinumtoxinA (BOTOX) Injections in Adult Participants for Treatment of Glabellar Lines

NCT05496335
View directory record Official record
Conditions
Glabellar Lines
Interventions
AGN-151586, BOTOX, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
10
States / cities
Newport Beach, California • San Diego, California • Greenwood Village, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 13, 2026, 5:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Botulinum-assisted Orbital Fat Augmentation With PRP (Platelet-rich-plasma)

NCT02244671
View directory record Official record
Conditions
Orbital Atrophy
Interventions
fat, PRP, botulinum toxin, botulinum toxin, PRP
Procedure · Drug · Device
Lead sponsor
Fox, Donald Munro, M.D., P.C.
Individual
Eligibility
21 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 19, 2018 · Synced Sep 13, 2026, 5:59 AM EDT
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

A Pilot Study Testing Onabotulinum Toxin A Versus Incobotulinum Toxin A Injections for Facial Wrinkles

NCT02019004
View directory record Official record
Conditions
Wrinkles
Interventions
Onabotulinum Toxin A, Incobotulinum Toxin A
Drug
Lead sponsor
Northwestern University
Other
Eligibility
20 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 13, 2026, 5:59 AM EDT
Completed Phase 3 Interventional Results available

BOTOX® Treatment in Pediatric Lower Limb Spasticity

NCT01603628
View directory record Official record
Conditions
Pediatrics, Muscle Spasticity, Cerebral Palsy
Interventions
botulinum toxin Type A, Normal Saline (Placebo)
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
2 Years to 16 Years
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
24
States / cities
Pasadena, California • Pomona, California • Aurora, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2018 · Synced Sep 13, 2026, 5:59 AM EDT
Completed Phase 4 Interventional

A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVÉDERM® Products, KYBELLA, CoolSculpting Elite and SkinMedica Products

NCT06783621
View directory record Official record
Conditions
Facial Contouring
Interventions
OnabotulinumtoxinA, JUVÉDERM, CoolSculpting Elite System, SkinMedica Products, KYBELLA
Drug · Device · Other
Lead sponsor
AbbVie
Industry
Eligibility
22 Years to 65 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
10
States / cities
Redondo Beach, California • Vista, California • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 13, 2026, 5:59 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Botox for the Treatment of Overactive Bladder Secondary to Benign Prostatic Obstruction

NCT01220726
View directory record Official record
Conditions
Overactive Bladder
Interventions
Botox, Placebo
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
40 Years to 90 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 25, 2019 · Synced Sep 13, 2026, 5:59 AM EDT
Completed No phase listed Observational

Urinary Retention Rates in Clinical Practice After Treatment With OnabotulinumtoxinA for Idiopathic Overactive Bladder

NCT02557971
View directory record Official record
Conditions
Urinary Bladder, Overactive
Interventions
onabotulinumtoxinA
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
7
States / cities
Davis, California • Irvine, California • Charlotte, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2016 · Synced Sep 13, 2026, 5:59 AM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate Botulinum Neurotoxin Serotype E (EB-001) in Reducing Musculoskeletal Pain in Abdominoplasty

NCT03429556
View directory record Official record
Conditions
Abdominoplasty
Interventions
Botulinum Neurotoxin Serotype E, Placebo
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
23 Years to 55 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
2
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Aug 4, 2019 · Synced Sep 13, 2026, 5:59 AM EDT
Completed Phase 3 Interventional Results available

Dysport® Adult Upper Limb Spasticity Extension Study

NCT01313312
View directory record Official record
Conditions
Nervous System Disorders
Interventions
Botulinum toxin type A
Biological
Lead sponsor
Ipsen
Industry
Eligibility
18 Years to 80 Years
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
13
States / cities
Downey, California • Fairfield, Connecticut • Boca Raton, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Sep 13, 2026, 5:59 AM EDT
Terminated Phase 4 Interventional Results available

The Movement of Botulinum Toxin Through the Lateral Gastrocnemius Muscle in Humans: An Expanded Examination

NCT03367429
View directory record Official record
Conditions
Stroke, Muscle Spasticity
Interventions
Botox
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
30 Years to 75 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 28, 2021 · Synced Sep 13, 2026, 5:59 AM EDT
Completed Phase 4 Interventional Results available

Patient Satisfaction Study of Combined Facial Treatment With BOTOX® Cosmetic, JUVÉDERM® and LATISSE® (HARMONY Study)

NCT02176356
View directory record Official record
Conditions
Facial Rhytides, Crow's Feet Lines, Glabellar Lines, Nasolabial Fold
Interventions
onabotulinumtoxinA, bimatoprost ophthalmic solution 0.03%, JUVÉDERM® ULTRA XC, JUVÉDERM® ULTRA PLUS XC, JUVÉDERM® VOLUMA® XC
Biological · Drug · Device
Lead sponsor
Allergan
Industry
Eligibility
35 Years to 65 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Sep 13, 2026, 5:59 AM EDT
Completed No phase listed Observational Results available

A Prospective Observational Study of Adult Strabismus

NCT02510040
View directory record Official record
Conditions
Convergence Insufficiency, Divergence Insufficiency, Hypertropia
Interventions
Prism, Orthoptic Exercises, Eye Muscle Surgery, Botox Injection
Device · Other · Procedure
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 5, 2023 · Synced Sep 13, 2026, 5:59 AM EDT
Recruiting Phase 3 Interventional

BOTOX® vs. XEOMIN® for Chronic Migraine

NCT05598723
View directory record Official record
Conditions
Chronic Migraine
Interventions
IncobotulinumtoxinA (XEOMIN®), OnabotulinumtoxinA (BOTOX®)
Drug
Lead sponsor
Naval Medical Center Camp Lejeune
Federal
Eligibility
18 Years to 89 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Jacksonville, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 13, 2026, 5:59 AM EDT
Not listed Phase 1 Interventional

New Approaches in Evaluating Patients' Response to Botulinum Toxins in the Treatment of Chronic Neck Pain and Back Pain

NCT02008136
View directory record Official record
Conditions
Cervicalgia, Low Back Pain
Interventions
Botulinum Toxins
Drug
Lead sponsor
VA Connecticut Healthcare System
Federal
Eligibility
18 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 6, 2017 · Synced Sep 13, 2026, 5:59 AM EDT
Active, not recruiting Phase 3 Interventional

Study to Compare the Efficacy and Safety of NT 201 (Botulinum Toxin) With Placebo for the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury

NCT03992404
View directory record Official record
Conditions
Lower Limb or Combined Lower Limb and Upper Limb Spasticity Due to Stroke or Traumatic Brain Injury
Interventions
NT 201, Placebo
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
18 Years to 85 Years
Enrollment
603 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
15
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 13, 2026, 5:59 AM EDT